We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

11 hedge funds and large institutions have $1.31M invested in Moleculin Biotech in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,127% more capital inflows, than outflows

Capital inflows: $460K | Capital outflows: $37.5K

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

22% more funds holding

Funds holding: 9 → 11 (+2)

2.58% more ownership

Funds ownership: 13.58% → 16.16% (+2.6%)

Holders
11
Holders Change
+2
Holders Change %
+22.22%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Armistice Capital
Armistice Capital
New York
+$386K
2
Renaissance Technologies
Renaissance Technologies
New York
+$31.7K
3
Truist Financial
Truist Financial
North Carolina
+$30.3K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$5.76K
5
LPL Financial
LPL Financial
California
+$5.76K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$37.5K

MBRX Hedge Fund Activity: Q3 2024 in Review

11 of the 6,986 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q3 2024, worth a combined $1.31M — up 19% from $1.1M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new MBRX positions and 0 closed out — a net gain of 2 holders — while 3 added to existing stakes and 1 trimmed.

The largest buyer was Armistice Capital, adding an estimated $386K. The largest seller was Vanguard Group, cutting an estimated $37.5K.

  • 11 institutional investors held Moleculin Biotech (MBRX) as of Q3 2024, up from 9 in Q2 2024.
  • Funds reported $1.31M of Moleculin Biotech stock for Q3 2024, up 19% quarter-over-quarter.
  • 2 funds opened new Moleculin Biotech positions in Q3 2024 and 0 closed out, a net change of +2 holders.
  • The largest Moleculin Biotech buyer in Q3 2024 was Armistice Capital, an estimated $386K added.
  • The largest Moleculin Biotech seller in Q3 2024 was Vanguard Group, an estimated $37.5K sold.

Based on aggregated 13F filings for Q3 2024.